This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.

This Seattle-based biotech, known for its immune medicine platform, reported a notable insider sale amid ongoing industry ...

Adaptive Biotechnologies maintains strong MRD segment momentum, but its stock is priced for high growth and margin ...

As of Wednesday, April 08, Adaptive Biotechnologies Corporation’s ADPT share price has surged by 10.28%, which has investors ...

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. Seattle’s Adaptive Biotechnologies, ...

Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 14.5% over the past month. The stock hit a new 52-week high of $12.93 in the previous session. Adaptive ...

The commercial-stage Adaptive booked $58.9 million in revenue for the period, a robust 36% improvement over the same quarter of 2024. Much of this growth was due to the company's efforts fighting ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...

Adaptive reported preliminary, unaudited revenue of approximately $72 million for the fourth quarter of 2025, representing a 51% increase compared to the same period in 2024. Full-year 2025 revenue ...